SG11201907744QA - Replacement of cytotoxic preconditioning before cellular immunotherapy - Google Patents

Replacement of cytotoxic preconditioning before cellular immunotherapy

Info

Publication number
SG11201907744QA
SG11201907744QA SG11201907744QA SG11201907744QA SG11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA SG 11201907744Q A SG11201907744Q A SG 11201907744QA
Authority
SG
Singapore
Prior art keywords
international
pct
cytotoxic preconditioning
cellular
cytotoxic
Prior art date
Application number
SG11201907744QA
Other languages
English (en)
Inventor
Theresa Ann Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of SG11201907744QA publication Critical patent/SG11201907744QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11201907744QA 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy SG11201907744QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US201862624454P 2018-01-31 2018-01-31
PCT/US2018/025517 WO2018183927A1 (fr) 2017-04-01 2018-03-30 Remplacement de préconditionnement cytotoxique avant une immunothérapie cellulaire

Publications (1)

Publication Number Publication Date
SG11201907744QA true SG11201907744QA (en) 2019-09-27

Family

ID=62111173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907744QA SG11201907744QA (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Country Status (13)

Country Link
US (2) US11219628B2 (fr)
EP (1) EP3490605B1 (fr)
JP (2) JP6748221B2 (fr)
KR (1) KR102509006B1 (fr)
CN (1) CN110475571B (fr)
AU (1) AU2018243753A1 (fr)
BR (1) BR112019020214A2 (fr)
CA (1) CA3054443A1 (fr)
ES (1) ES2954311T3 (fr)
IL (1) IL269209B2 (fr)
MX (1) MX2019011679A (fr)
SG (1) SG11201907744QA (fr)
WO (1) WO2018183927A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2018183927A1 (fr) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Remplacement de préconditionnement cytotoxique avant une immunothérapie cellulaire
EP3634528B1 (fr) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Dispositifs de déplacement de fluide intravasculaire, systèmes et procédés d'utilisation
EP3710076B1 (fr) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Dispositifs de déplacement de liquide intravasculaire, systèmes et procédés d'utilisation
EP4085965A1 (fr) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Pompes à sang intravasculaires et procédés d'utilisation et de fabrication
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
EP3632446B3 (fr) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Thérapies immunoablatives
EP3488851A1 (fr) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives
EP3706721A1 (fr) * 2018-11-14 2020-09-16 AVM Biotechnology, LLC Formulation stable de glucocorticoïde
US20220016168A1 (en) * 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US11964145B2 (en) 2019-07-12 2024-04-23 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
WO2021062265A1 (fr) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Dispositifs et systèmes de pompes à sang intravasculaires et leurs procédés d'utilisation et de commande
MX2022005389A (es) * 2019-11-06 2022-07-27 Kite Pharma Inc Terapia de celulas t con receptor de antigeno quimerico.
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
US20220016165A1 (en) * 2020-02-20 2022-01-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
US20230096897A1 (en) 2020-02-28 2023-03-30 Avm Biotechnology, Llc Lymphocyte Population and Methods for Producing Same
EP4132585A2 (fr) * 2020-04-10 2023-02-15 North Carolina State University Transduction virale améliorée de cellules de mammifère à l'aide d'échafaudages de matériaux
CN111443210B (zh) * 2020-04-10 2023-09-22 青海大学附属医院 泡型包虫病早期诊疗生物标志物及其应用
EP4142736A1 (fr) 2020-04-29 2023-03-08 AVM Biotechnology, LLC Modulateurs de récepteurs de glucocorticoïde (gr) destinés au traitement d'un virus sars-cov-2
WO2021247000A1 (fr) 2020-06-01 2021-12-09 Avm Biotechnology, Llc Méthodes de traitement faisant appel à des agents de modulation d'icam
WO2022049572A1 (fr) * 2020-09-01 2022-03-10 The National Institute for Biotechnology in the Negev Ltd. Restauration d'un système immunitaire par thérapie cellulaire
CN113322233A (zh) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 一种改进的基于新生抗原反应性t细胞的制备方法及应用
CN113480614B (zh) * 2021-08-13 2023-01-10 中国人民解放军总医院 一类靶向pd-l1的超高亲和力小蛋白及用途
WO2023034377A1 (fr) 2021-09-01 2023-03-09 Avm Biotechnology, Llc Population de lymphocytes et leurs méthodes de production
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN116606352B (zh) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
ES2320314T3 (es) 1997-12-16 2009-05-21 University Of Zurich Diagnostico para encefalopatia espongiforme transmisible.
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
KR20050013531A (ko) 2002-03-15 2005-02-04 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) 세포의 아시알로결정자 및 당접합체를 이용하여 세포를조직 및 기관으로 표적화하는 방법 및 이를 위한 조성물
NZ584663A (en) 2002-05-17 2011-09-30 Celgene Corp Use of immunomodulatory amino-dione derivatives for treating leukemia
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
SI1835924T1 (sl) 2004-12-23 2013-12-31 Ethicon, Incorporated Zdravljenje Parkinsonove bolezni in sorodnih obolenj z uporabo celic, pridobljenih post partum
WO2006114115A1 (fr) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer
CA2615615A1 (fr) 2005-07-22 2007-02-01 Y's Therapeutics Co., Ltd. Anticorps anti-cd26 et methodes d'utilisation de ces derniers
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
MX2010012576A (es) * 2008-05-23 2011-04-05 Argos Therapeutics Inc Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152187A1 (fr) 2008-06-09 2009-12-17 American Stem Cell, Inc. Augmentation de l'efficacité de la thérapie cellulaire comprenant le traitement avec l'alpha(1,3)fucosyltransférase
WO2009152186A1 (fr) 2008-06-09 2009-12-17 American Stem Cell, Inc. Procédés permettant d’améliorer l’efficacité de la thérapie cellulaire, incluant le traitement au moyen d’inhibiteurs de la peptidase cd26
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
AU2011291651B2 (en) * 2010-08-18 2016-01-14 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
CN103442768A (zh) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 治疗癌的组合物和方法
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
JP6765966B2 (ja) * 2014-04-07 2020-10-07 ノバルティス アーゲー 抗ｃｄ１９キメラ抗原受容体を使用する癌の処置
CA2973529A1 (fr) * 2015-01-26 2016-08-04 Cellectis Recepteur d'antigene chimerique a chaines multiples specifique de cll1
US9855298B2 (en) * 2015-05-28 2018-01-02 Kite Pharma, Inc. Methods of conditioning patients for T cell therapy
JP2019536786A (ja) * 2016-11-30 2019-12-19 イントレキソン コーポレーション ステロイドの投与および免疫療法
WO2018183927A1 (fr) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Remplacement de préconditionnement cytotoxique avant une immunothérapie cellulaire

Also Published As

Publication number Publication date
US20180296572A1 (en) 2018-10-18
CN110475571B (zh) 2023-04-04
KR20190130624A (ko) 2019-11-22
AU2018243753A1 (en) 2019-10-10
ES2954311T3 (es) 2023-11-21
JP6748221B2 (ja) 2020-08-26
CN110475571A (zh) 2019-11-19
KR102509006B1 (ko) 2023-03-13
WO2018183927A1 (fr) 2018-10-04
BR112019020214A2 (pt) 2020-04-22
JP2020114837A (ja) 2020-07-30
US11219628B2 (en) 2022-01-11
EP3490605C0 (fr) 2023-06-07
IL269209B2 (en) 2023-11-01
EP3490605A1 (fr) 2019-06-05
MX2019011679A (es) 2019-11-01
EP3490605B1 (fr) 2023-06-07
IL269209B1 (en) 2023-07-01
JP2019515888A (ja) 2019-06-13
IL269209A (en) 2019-11-28
CA3054443A1 (fr) 2018-10-14
JP7162632B2 (ja) 2022-10-28
US20220160729A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201811074RA (en) Nant cancer vaccine
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808108XA (en) Synthesis of indazoles
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201805001UA (en) Method of treating influenza a
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900043TA (en) Antibody formulations
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900361RA (en) Methods of treating prostate cancer
SG11201810940XA (en) Methods of treating pancreatic cancer